news
Johnson & Johnson “most valuable” pharma brand, says report
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
List view / Grid view
Pfizer
article
The intricacies of rising drug prices in the US
Following 250 US drug price increases in 2020 already, this article explores why costs are rising, what changes could ensure brand reputations remain intact and what manufacturers can do to ensure they get their share.
article
The biggest pharma merger and acquisition deals of 2019
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
news
NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
news
LogiPharma announces preliminary speaker lineup and agenda
Preliminary agenda and speakers announced for LogiPharma, The World’s Leading Pharma Supply Chain Event (21 – 23 April) 2020.
news
Top five pharma companies saw overall decline in Q3 2019
Research has found that the top five pharmaceutical companies averaged a Market Capitalisation decline of five percent in Q3 of 2019.
news
NICE approves breast cancer treatment through Cancer Drugs Fund
NICE has approved palbociclib through the Cancer Drugs Fund, meaning that women with advanced breast cancer who have already received hormone therapy will now be eligible for palbociclib on the NHS.
article
IoT could transform the pharma industry through these steps
Adopting IoT systems as a pharmaceutical company can provide many opportunities but achieving success can be difficult. James Steiner explains how to effectively integrate IoT solutions into pharma.
article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
news
XTANDI® treatment granted priority review by FDA
XTANDI® sNDA seeks to add an indication for men with prostate cancer that's spread but is sensitive to hormone therapy.
news
Two lots of migraine medication have been recalled
Pfizer has volountarily recalled the migraine medication Relpax because of the potential presence of Pseudomonas and Burkholderia.
article
Climate change: how pharma will profit from a warming planet
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
news
FTC investigates contracts regarding autoimmune disease drug, Remicade
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
news
RUXIENCE™ biosimilar granted approval from FDA
The FDA has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for treatment of non-Hogkin’s lymphoma and other conditions.
news
FDA approves nine generics for Lyrica drug
The FDA has announced that it has granted approval to the first nine generic drug applications for Pfizer’s Lyrica treatment.
